12 January 2024
IXICO plc
("IXICO" or the "Company")
CEO Succession
IXICO plc, (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience, announces that Giulio Cerroni has informed the Board of his intention to retire from his role as Chief Executive Officer ("CEO") and director of the Company by the end of 2024 in accordance with his notice period and to ensure a smooth handover of responsibilities. The Board has begun the process to appoint a new CEO in line with its succession plan and will update the market in due course.
For further information please contact:
| IXICO plc | +44 (0) 20 3763 7499 | ||
| Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| ||
|
|
| ||
| Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) | +44 (0) 20 7220 0500 | ||
| Giles Balleny / Dan Hodkinson (Corporate Finance) Michael F Johnson / Tamar Cranford Smith (Sales) |
|
| |
This announcement contains inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR.
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.